FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129682084> ?p ?o ?g. }

• W2129682084 endingPage "14" @default.
• W2129682084 startingPage "8" @default.
• W2129682084 abstract "Background While some retrospective studies have suggested that β-blocker use in patients with COPD is associated with a reduction in the frequency of acute exacerbations and lower mortality, there is concern that their use in patients with severe COPD on home oxygen may be harmful. Methods Subjects with Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 2–4 COPD participating in a prospective follow-up of the COPDGene cohort, a multicentre observational cohort of current and former smokers were recruited. Total and severe exacerbation rates were compared between groups categorised by β-blocker use on longitudinal follow-up using negative binomial regression analyses, after adjustment for demographics, airflow obstruction, %emphysema on CT, respiratory medications, presence of coronary artery disease, congestive heart failure and coronary artery calcification, and after adjustment for propensity to prescribe β-blockers. Results 3464 subjects were included. During a median of 2.1 years of follow-up, β-blocker use was associated with a significantly lower rate of total (incidence risk ratio (IRR) 0.73, 95% CI 0.60 to 0.90; p=0.003) and severe exacerbations (IRR 0.67, 95% CI 0.48 to 0.93; p=0.016). In those with GOLD stage 3 and 4 and on home oxygen, use of β-blockers was again associated with a reduction in the rate of total (IRR 0.33, 95% CI 0.19 to 0.58; p<0.001) and severe exacerbations (IRR 0.35, 95% CI 0.16 to 0.76; p=0.008). Exacerbation reduction was greatest in GOLD stage B. There was no difference in all-cause mortality with β-blocker use. Conclusions β-Blockers are associated with a significant reduction in COPD exacerbations regardless of severity of airflow obstruction. The findings of this study should be tested in a randomised, placebo-controlled trial. Trial registration number (ClinicalTrials.gov NCT00608764 )." @default.
• W2129682084 created "2016-06-24" @default.
• W2129682084 creator A5001253697 @default.
• W2129682084 creator A5031256327 @default.
• W2129682084 creator A5035524361 @default.
• W2129682084 creator A5037288031 @default.
• W2129682084 creator A5044972915 @default.
• W2129682084 creator A5045141623 @default.
• W2129682084 creator A5046399622 @default.
• W2129682084 creator A5050358373 @default.
• W2129682084 creator A5053755396 @default.
• W2129682084 creator A5064775862 @default.
• W2129682084 creator A5079665496 @default.
• W2129682084 creator A5083798425 @default.
• W2129682084 date "2015-08-17" @default.
• W2129682084 modified "2023-10-16" @default.
• W2129682084 title "β-Blockers are associated with a reduction in COPD exacerbations" @default.
• W2129682084 cites W1893937985 @default.
• W2129682084 cites W1960263711 @default.
• W2129682084 cites W1962826533 @default.
• W2129682084 cites W1966494514 @default.
• W2129682084 cites W1979634869 @default.
• W2129682084 cites W2008043724 @default.
• W2129682084 cites W2008212067 @default.
• W2129682084 cites W2009197337 @default.
• W2129682084 cites W2011204376 @default.
• W2129682084 cites W2014443718 @default.
• W2129682084 cites W2014948273 @default.
• W2129682084 cites W2014951154 @default.
• W2129682084 cites W2020707691 @default.
• W2129682084 cites W2020720946 @default.
• W2129682084 cites W2036193982 @default.
• W2129682084 cites W2038973797 @default.
• W2129682084 cites W2046095585 @default.
• W2129682084 cites W2052247326 @default.
• W2129682084 cites W2074016661 @default.
• W2129682084 cites W2082907106 @default.
• W2129682084 cites W2084632272 @default.
• W2129682084 cites W2093627517 @default.
• W2129682084 cites W2100907993 @default.
• W2129682084 cites W2101128680 @default.
• W2129682084 cites W2102018049 @default.
• W2129682084 cites W2110429964 @default.
• W2129682084 cites W2113972884 @default.
• W2129682084 cites W2114196542 @default.
• W2129682084 cites W2125418504 @default.
• W2129682084 cites W2127951128 @default.
• W2129682084 cites W2128669435 @default.
• W2129682084 cites W2130230386 @default.
• W2129682084 cites W2130479174 @default.
• W2129682084 cites W2132683688 @default.
• W2129682084 cites W2147549437 @default.
• W2129682084 cites W2149275141 @default.
• W2129682084 cites W2150934575 @default.
• W2129682084 cites W2159230973 @default.
• W2129682084 cites W2161987121 @default.
• W2129682084 cites W2164132830 @default.
• W2129682084 cites W2166208300 @default.
• W2129682084 cites W2170432816 @default.
• W2129682084 cites W2312997470 @default.
• W2129682084 doi "https://doi.org/10.1136/thoraxjnl-2015-207251" @default.
• W2129682084 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5154678" @default.
• W2129682084 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26283710" @default.
• W2129682084 hasPublicationYear "2015" @default.
• W2129682084 type Work @default.
• W2129682084 sameAs 2129682084 @default.
• W2129682084 citedByCount "97" @default.
• W2129682084 countsByYear W21296820842016 @default.
• W2129682084 countsByYear W21296820842017 @default.
• W2129682084 countsByYear W21296820842018 @default.
• W2129682084 countsByYear W21296820842019 @default.
• W2129682084 countsByYear W21296820842020 @default.
• W2129682084 countsByYear W21296820842021 @default.
• W2129682084 countsByYear W21296820842022 @default.
• W2129682084 countsByYear W21296820842023 @default.
• W2129682084 crossrefType "journal-article" @default.
• W2129682084 hasAuthorship W2129682084A5001253697 @default.
• W2129682084 hasAuthorship W2129682084A5031256327 @default.
• W2129682084 hasAuthorship W2129682084A5035524361 @default.
• W2129682084 hasAuthorship W2129682084A5037288031 @default.
• W2129682084 hasAuthorship W2129682084A5044972915 @default.
• W2129682084 hasAuthorship W2129682084A5045141623 @default.
• W2129682084 hasAuthorship W2129682084A5046399622 @default.
• W2129682084 hasAuthorship W2129682084A5050358373 @default.
• W2129682084 hasAuthorship W2129682084A5053755396 @default.
• W2129682084 hasAuthorship W2129682084A5064775862 @default.
• W2129682084 hasAuthorship W2129682084A5079665496 @default.
• W2129682084 hasAuthorship W2129682084A5083798425 @default.
• W2129682084 hasBestOaLocation W21296820841 @default.
• W2129682084 hasConcept C126322002 @default.
• W2129682084 hasConcept C164705383 @default.
• W2129682084 hasConcept C167135981 @default.
• W2129682084 hasConcept C167704817 @default.
• W2129682084 hasConcept C188816634 @default.
• W2129682084 hasConcept C201903717 @default.
• W2129682084 hasConcept C2776780178 @default.
• W2129682084 hasConcept C2777014857 @default.
• W2129682084 hasConcept C2777104659 @default.

• next